CT-AMT-130-01
62 evidence topics · 21 sources
Objective
Safety and proof of concept in a first-in-human study
Objective described in March 2022
Location and study date
United States study sites in the registry record
| Site | City |
|---|---|
| University of Alabama at Birmingham | “Birmingham” |
| University of Arizona (Surgical Site Only) | “Tucson” |
| University of California, San Francisco | “San Francisco” |
| CenExel Rocky Mountain Clinical Research | “Englewood” |
| Rush University Medical Center | “Chicago” |
| Johns Hopkins University | “Baltimore” |
| University of Michigan Department of Neurology | “Ann Arbor” |
| Ohio State University | “Columbus” |
| Vanderbilt University Medical Center | “Nashville” |
| The University of Texas | “Houston” |
| Virginia Commonwealth University VCU School of Medicine, Department of Neurology | “Richmond” |
| University of Washington Medical Center | “Seattle” |
Study dates in the registry record
| Date | Registry value |
|---|---|
| Study start (actual) | “2019-09-06” |
| Primary completion (estimated) | “2029-06” |
| Study completion (estimated) | “2029-12” |
| Last update posted | “2025-10-21” |
First participants treated in the United States, June 2020
Study dates in the original registry record, October 2019, superseded
| Field | Registry value |
|---|---|
| Version | “Viewing V1 (2019-10-07)” |
| Study start | “2019-10 [Estimated]” |
| Primary completion | “2022-12 [Estimated]” |
| Study completion | “2026-05 [Estimated]” |
Study design
Design in the current registry record
Design fields in the current registry record
| Field | Registry value |
|---|---|
| Allocation | “Non-Randomized” |
| Intervention model | “Sequential” |
| Masking | “None (Open Label)” |
Randomized, quadruple-masked parallel design with an 18-month core period: registry version 1, October 2019, superseded
Randomized, triple-masked sequential design with crossover: registry version 33, October 2024, superseded
| Field | Registry value |
|---|---|
| Version | “Viewing V33 (2024-10-22)” |
| Interventional study model | “Sequential Assignment” |
| Masking | “Triple (Participant, Investigator, Outcomes Assessor)” |
| Allocation | “Randomized” |
| Enrollment | “37 [Estimated]” |
Blinded core period of 18 months at first dosing, June 2020, superseded
Blinded 12-month core period followed by five years of follow-up, March 2022
Cohort 3 as first planned: alternative stereotactic navigation, December 2021, superseded in June 2023
Cohort 3 redesigned to study perioperative immunosuppression, June 2023
Cohort 3: blinded randomization to high or low dose
Cohort 4: high dose in participants with lower striatal volumes
Eligibility criteria
Inclusion criteria in the current registry record
Striatal volume criteria: minimum volumes in Cohorts 1 to 3 and lower volumes in Cohort 4
Selected exclusion criteria in the current registry record
Eligibility in the original registry record, October 2019, superseded
Treatment
Doses and route in the current registry record
Imitation (sham) surgery in Cohorts 1 and 2
Imitation surgery with partial-thickness burr holes: registry version 1, October 2019, superseded
Cohort 4: high dose with perioperative dexamethasone
Study outcomes
Rationale for using adverse events as the primary endpoint
Primary outcome: number and type of adverse events at 12 months
First-in-human trial with staged dosing reviewed by the Data Safety Monitoring Board
Secondary outcome: persistence of AMT-130 in the brain
Exploratory outcomes in the current registry record
| Exploratory outcome | Registry entry |
|---|---|
| Cerebrospinal fluid mutant huntingtin | “CSF Mutant Protein (fM)” |
| Neurofilament light chain | “CSF/Serum Neurofilament Light Chain (pg/mL)” |
| Rating scale | “Unified Huntington Disease Rating Scale (UHDRS)” |
| Quantitative motor testing | “Quantitative Motor (Q-Motor) Testing” |
| Imaging | “Magnetic Resonance Imaging (MRI)” |
| Health-related quality of life | “Neuro-QoL Measures” |
Additional exploratory outcomes in registry version 1, October 2019
Limitation of cerebrospinal fluid mutant huntingtin as a measure of brain levels
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment at first dosing, June 2020, superseded
Participants in Cohorts 1 and 2 by arm
Planned size of Cohort 3, December 2023
Estimated total enrollment in the current registry record
| Field | Registry value |
|---|---|
| Enrollment (estimated) | “43” |
Description of analysis sets
Participants evaluable for biomarkers in the low-dose cohort, June 2022
Comparators and exclusion of crossover participants in the June 2023 interim analysis
Results
Participant disposition
Enrollment of Cohorts 1 and 2 completed, March 2022
Crossover of control participants, 2022 to 2023
Cohort 3 enrollment completed, February 2025
Cohort 4 recruited in October 2025 and dosed in the fourth quarter of 2025
Baseline characteristics
First four participants in the low-dose cohort, December 2021
Low-dose cohort of 10 participants, June 2022
Cohort 4 baseline characteristics
| Characteristic (mean or %) | AMT-130 high-dose Cohort 4 (n=6) |
|---|---|
| Sex, males (%) | “16.7” |
| Age | “43.7” |
| CAG repeats | “44.5” |
| DCL = 3, 4 (%) | “16.7, 83.3” |
| TFC | “12.0” |
Efficacy results
First four participants at one year, December 2021
Low-dose cohort at 12 months: cerebrospinal fluid mutant huntingtin, June 2022
Low-dose cohort at 12 months: cerebrospinal fluid neurofilament light chain, June 2022
U.S. interim analysis: clinical measures against baseline, controls, and a TRACK-HD natural history cohort, June 2023
U.S. interim analysis: biomarkers and brain volume, June 2023
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
First four participants at one year, December 2021
Low-dose cohort at 12 months: deep vein thrombosis and postoperative delirium, June 2022
High-dose procedures paused after suspected unexpected serious adverse reactions, August 2022
High-dose treatment resumed with additional monitoring, October 2022
U.S. interim analysis: serious adverse events and suspected unexpected serious adverse reactions, June 2023
Cohort 3: serious adverse events related to immunosuppression
Cohort 4: treatment-related central nervous system inflammation
Study limitations
Summary
- Changed blinding and registry inconsistencies: the current ClinicalTrials.gov record lists allocation as non-randomized and masking as none (open label), while its official title describes a randomized, double-blind, sham control and open-label study. Version 1 (2019) listed a randomized, quadruple-masked design with an estimated enrollment of 26 and a blinded 18-month core period; version 33 (2024) listed a randomized, triple-masked design with an estimated enrollment of 37 and a blinded 12-month core period; the current record lists an estimated enrollment of 43. Cohort 4 is open-label.
- Short randomized comparison: the sham comparison in Cohorts 1 and 2 covered the blinded 12-month period, after which sham participants could cross over. Four of the six control participants in the high-dose cohort crossed over and the other two did not meet the inclusion criteria, and interim analyses compared treated participants with control participants only up to 12 months and excluded efficacy data from crossover participants.
- Small numbers: Cohorts 1 and 2 randomized 26 participants (six low dose, 10 high dose, 10 sham); Cohort 3 enrolled 12 and Cohort 4 six.
- Safety as the primary outcome: the study is designed to establish safety and proof-of-concept, and the registered primary outcome is adverse events at 12 months.
- Target engagement: the company states that CSF mutant huntingtin is not believed to be materially representative of mutant huntingtin in the targeted brain regions, and one commentary noted that there are no data on mutant HTT lowering.
- Protocol changes: version 1 required ≥44 CAG repeats and an imitation surgery with bilateral partial thickness burr holes; the current record requires ≥40 CAG repeats and a simulated procedure with skin incisions only and no burr holes. Cohort 3 was first planned to study alternative stereotactic navigation systems and was redesigned to study perioperative immunosuppression.